Summit Therapeutics Inc. Interest Expense Nonoperating
Summit Therapeutics Inc. (SMMT) reported Interest Expense Nonoperating of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-02-23
- Summit Therapeutics Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. interest expense nonoperating for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Summit Therapeutics Inc. interest expense nonoperating for fiscal 2024 was $8.69M, a 47.23% decline from fiscal 2023.
- Summit Therapeutics Inc. interest expense nonoperating for fiscal 2023 was $16.46M, a 274.03% increase from fiscal 2022.
- Summit Therapeutics Inc. interest expense nonoperating for fiscal 2022 was $4.40M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-20 | $0.00 derived: sum of 2 quarters · filed 2025-10-20 | $0.00 10-Q · filed 2025-10-20 | $9.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $9.00K derived: sum of 3 quarters · filed 2026-02-23 | $2.46M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $9.00K derived: sum of 2 quarters · filed 2026-02-23 | $2.46M derived: sum of 3 quarters · filed 2026-02-23 | $5.57M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.46M derived: sum of 2 quarters · filed 2026-02-23 | $5.57M derived: sum of 3 quarters · filed 2026-02-23 | $8.69M 10-K · filed 2026-02-23 |
| 2024-09-30 | $2.45M 10-Q · filed 2025-10-20 | $5.56M derived: sum of 2 quarters · filed 2025-10-20 | $8.68M 10-Q · filed 2025-10-20 | |
| 2024-06-30 | $3.10M 10-Q · filed 2025-08-11 | $6.22M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $3.12M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $16.46M 10-K · filed 2026-02-23 | |||
| 2022-12-31 | $4.40M 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |